Multiple Sclerosis: Update Bulletin [March 2016]
Gain new KOL insights on the latest events happening in multiple sclerosis (MS):
Topics covered include opinions about the discontinuation of Teva’s/Active Biotech’s higher-dose laquinimod Phase III studies; reactions to European and Canadian regulatory authority recommendations designed to inform physicians and patients about the increased risk of progressive multifocal leukoencephalopathy (PML) and basal cell carcinoma associated with Novartis’ Gilenya (fingolimod), as well as opinions on GeNeuro’s GNbAC1 antibody undergoing Phase IIb evaluation in relapsing remitting multiple sclerosis.
Key Questions Answered in this Update Bulletin:
Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook